MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1

Cancer Cell International

Volumn 14, Issue 1, 2014, Pages

  Chen, Xiao nan ^a   Wang, Ke feng ^a   Xu, Zhen qun ^a   Li, Shi jie ^a   Liu, Qiang ^a   Fu, Dong hui ^a   Wang, Xia ^a   Wu, Bin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Akt1; Apoptosis; Bcl w; Bladder cancer; miR 133b; Proliferation

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; MICRORNA; MICRORNA 133B; PROTEIN AKT1; PROTEIN BCL W; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84905974977     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-014-0070-3     Document Type: Article

References (40)

1. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 2006, 103(11):4034-4039. 10.1073/pnas.0510928103, 16495412.
2. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27(45):5959-5974. 10.1038/onc.2008.274, 18836476.
3. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302(1):1-12. 10.1016/j.ydbio.2006.08.028, 16989803.
4. Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev 2010, 11(4):905-911. 21133599.
5. Catto JW, Miah S, Owen HC, Bryant H, Myers K, Dudziec E, Larre´ S, Milo M, Rehman I, Rosario DJ, Di Martino E, Knowles MA, Meuth M, Harris AL, Hamdy FC. Distinct MicroRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 2009, 69(21):8472-8481. 10.1158/0008-5472.CAN-09-0744, 19843843.
6. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25(5):387-392. 10.1016/j.urolonc.2007.01.019, 17826655.
7. Bandre´s E, Cubedo E, Agirre X, Malumbres R, Za´rate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo´ M, Garci´a-Foncillas J. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29. 10.1186/1476-4598-5-29, 16854228.
8. Goldsmith KC, Lestini BJ, Gross M, Ip L, Bhumbla A, Zhang X, Zhao H, Liu X, Hogarty MD. BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death Differ 2010, 17(5):872-882. 10.1038/cdd.2009.171, 19893570.
9. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009, 16(3):360-367. 10.1038/cdd.2008.137, 18806758.
10. O'Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DC, Strasser A. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001, 8(5):486-494. 10.1038/sj.cdd.4400835, 11423909.
11. Pritchard DM, Print C, O'Reilly L, Adams JM, Potten CS, Hickman JA. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 2000, 19(34):3955-3959. 10.1038/sj.onc.1203729, 10951589.
12. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26(9):1324-1337. 10.1038/sj.onc.1210220, 17322918.
13. Courchesne SL, Karch C, Pazyra-Murphy MF, Segal RA. Sensory neuropathy due to loss of Bcl-w. J Neurosci 2011, 31(5):1624-1634. 10.1523/JNEUROSCI.3347-10.2011, 21289171.
14. Kumar A, Rajendran V, Sethumadhavan R, Purohit R. AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal 2013, 2013:756134. 24327805.
15. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988-1004. 10.1038/nrd1902, 16341064.
16. Kumar A, Purohit R. Cancer associated E17K mutation causes rapid conformational drift in AKT1 Pleckstrin Homology (PH) domain. PLoS One 2013, 8(5):e64364. 10.1371/journal.pone.0064364, 23741320.
17. Kim MO, Lee MH, Oi N, Kim SH, Bae KB, Huang Z, Kim DJ, Reddy K, Lee SY, Park SJ, Kim JY, Xie H, Kundu JK, Ryoo ZY, Bode AM, Surh YJ, Dong Z: [6]-Shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2. Carcinogenesis 2013 . Epub ahead of print..
18. Gai L, Cai N, Wang L, Xu X, Kong X. Ursolic acid induces apoptosis via Akt/NF-κB signaling suppression in T24 human bladder cancer cells. Mol Med Rep 2013, 7(5):1673-1677. 23483134.
19. Juanpere N, Agell L, Lorenzo M, De Muga S, Lo´pez-Vilaro´ L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Herna´ndez S. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol 2012, 43(10):1573-1582. 10.1016/j.humpath.2011.10.026, 22417847.
20. Lin PY, Yang PC. Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 2011, 3(8):436-437. 10.1002/emmm.201100155, 21739607.
21. Parasramka MA, Ho E, Williams DE, Dashwood RH. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals. Mol Carcinog 2012, 51(3):213-230. 10.1002/mc.20822, 21739482.
22. Hummel R, Maurer J, Haier J. MicroRNAs in brain tumors: a new diagnostic and therapeutic perspective?. Mol Neurobiol 2011, 44(3):223-234. 10.1007/s12035-011-8197-x, 21739238.
23. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
24. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6(4):259-269. 10.1038/nrc1840, 16557279.
25. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003, 113(6):673-676. 10.1016/S0092-8674(03)00428-8, 12809598.
26. Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andre´n O, Olsson B, Klinga-Levan K. A miRNA expression signature that separates between normal and malignant prostate tissues. Cancer Cell Int 2011, 11(1):14. 10.1186/1475-2867-11-14, 21619623.
27. Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, Phung NA, McLaughlin S, Libertino JA, Whitney D, Summerhayes IC. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2010, 28(1):39-48. 10.1016/j.urolonc.2008.06.006, 18799331.
28. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009, 219(2):214-221. 10.1002/path.2586, 19593777.
29. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, Liedberg F, Chebil G, Gudjonsson S, Borg A, Ma˚nsson W, Rovira C, Ho¨glund M. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 2009, 124(9):2236-2242. 10.1002/ijc.24183, 19127597.
30. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H. MiR-145, miR-133a and miR-133b: tumor-suppr-Essive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010, 127(12):2804-2814. 10.1002/ijc.25284, 21351259.
31. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N, Nakagawa M. MiR-145 and mrR-133a function as tumor suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 2010, 102(5):883-891. 10.1038/sj.bjc.6605570, 20160723.
32. Hu G, Chen D, Li X, Yang K, Wang H, Wu W. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther 2010, 10(2):190-197. 10.4161/cbt.10.2.12186, 20505319.
33. Lee HW, Lee SS, Lee SJ, Um HD. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res 2003, 63(5):1093-1100. 12615727.
34. Bae IH, Park MJ, Yoon SH, Kang SW, Lee SS, Choi KM, Um HD. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006, 66(10):4991-4995. 10.1158/0008-5472.CAN-05-4254, 16707418.
35. Guo WJ, Wang AY, Gao C. Apoptosis and expression of apoptosis-related proteins Bcl-2, Bcl-xL and Bcl-w in human colon adenocarcinoma. World Chin J Degestology 2009, 17(25):2589-2594.
36. Sun XF, Sun ZY, Pan B, Li L, Shen W. Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer. Mol Biol Rep 2012, 39(5):5631-5636. 10.1007/s11033-011-1369-y, 22189542.
37. Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF, Knowles MA. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 2010, 29(1):150-155. 10.1038/onc.2009.315, 19802009.
38. Crawford M, Batte K, Yu L, Wu X, Nuovo GJ, Marsh CB, Otterson GA, Nana-Sinkam SP. microRNA 133B targets prosurvival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009, 388(3):483-489. 10.1016/j.bbrc.2009.07.143, 19654003.
39. Wei Y, Hegarty JP, Berg A, Chen X, West G, Kelly AA, Wang Y, Poritz LS, Koltun WA, Lin Z. NKX2-3 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells. PLoS One 2011, 6(5):e20454. 10.1371/journal.pone.0020154.
40. Shen L, Li J, Xu L, Ma J, Li H, Xiao X, Zhao J, Fang L. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 2012, 3(3):475-480. 22969914.